PMID: 9549357Apr 29, 1998Paper

Drug delivery system (DDS) for the use of antisense oligodeoxynucleotide phosphorothioate in controlling gene expression

Nihon rinsho. Japanese journal of clinical medicine
N MaedaN Yamamoto

Abstract

Synthetic antisense oligodeoxynucleotide phosphorothioates (ODNs) are widely used as therapeutic tools in various in vitro and in vivo systems. Here, we applied ODNs to inhibit viral gene expression. Human T-cell leukemia virus type I (HTLV-I) is a retrovirus, and is closely linked to adult T-cell leukemia (ATL), HTLV-I-associated myelopathy/tropical spastic paraparesis(HAM/TSP), and other HTLV-I-associated diseases. With an attempt to control viral replication in vitro, ODNs to HTLV-I tax gene were synthesized and applied. In addition, 1,2-dioleoyloxy-3-(trimethylammonio) propane, DOTAP as a drug delivery system, was exploited to increase the cellular uptake of ODNs. Combination of ODNs and DOTAP was more effective to suppress viral antigen expression than ODNs only. Therefore this combination method may be useful in clinical trials for HTLV-I-associated diseases.

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.